CAMBRIDGE, England, June 17, 2024 /PRNewswire/ — PartitionBio™ received a grant from the Bill & Melinda Gates Foundation to utilise its proprietary biocondensate-based macromolecule delivery platform for the transfection of cells with nucleic acids. The purpose of the project is to deploy the breakthrough technology as a novel non-viral tool for the introduction of protein-encoding RNA or DNA into human cells. The long-term aim of the work is to enable a more efficient approach for the expression of therapeutic proteins in patients.
About PartitionBio™
PartitionBio™ is a Cambridge (UK) based biotech start-up company offering a revolutionary technology platform for the non-viral delivery of a broad spectrum of macromolecules with therapeutic potential across the cell membrane. Possible payloads for the shuttle condensates include antibodies, proteins, peptides and nucleic acids.
Contact:
Helen Kent-Armes
H.armes@partitionbio.co.uk
07747 806 905
View original content:https://www.prnewswire.co.uk/news-releases/partitionbio-awarded-grant-to-exploit-its-novel-biologics-shuttle-platform-for-therapeutic-nucleic-acids-delivery-302174204.html
Disclaimer: The above press release comes to you under an arrangement with PR Newswire. TheNewsThisWeek.co.uk takes no editorial responsibility for the same.